Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer.

MLA

Denkert, Carsten, et al. “Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 29, no. 8, Apr. 2023, pp. 1569–81. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-22-1989.

APA

Denkert, C., Lambertini, C., Fasching, P. A., Pogue-Geile, K. L., Mano, M. S., Untch, M., Wolmark, N., Huang, C.-S., Loibl, S., Mamounas, E. P., Geyer, C. E., Lucas, P. C., Boulet, T., Song, C., Lewis, G. D., Nowicka, M., de Haas, S., & Basik, M. (2023). Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 29(8), 1569–1581. https://doi.org/10.1158/1078-0432.CCR-22-1989

Chicago

Denkert, Carsten, Chiara Lambertini, Peter A Fasching, Katherine L Pogue-Geile, Max S Mano, Michael Untch, Norman Wolmark, et al. 2023. “Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 29 (8): 1569–81. doi:10.1158/1078-0432.CCR-22-1989.